Next Article in Journal
Clinical and Pathological Characteristics of Bladder Cancer in Patients Aged 18–45 Undergoing Transurethral Resection of Bladder Tumor
Previous Article in Journal
Establishing Local Diagnostic Reference Levels for Head Computed Tomography Examinations
Previous Article in Special Issue
Amyotrophic Lateral Sclerosis—The Complex Phenotype—From an Epidemiological Perspective: A Focus on Extrapyramidal and Non-Motor Features
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 12
Issue 11
10.3390/biomedicines12112447
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Biomedicines 2022, 10(5), 985.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Musumeci et al. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer’s Disease. Biomedicines 2022, 10, 985

by
Teresa Musumeci
1,†,
Giulia Di Benedetto
2,†,
Claudia Carbone
1,
Angela Bonaccorso
1,
Giovanni Amato
1,
Maria Josè Lo Faro
3,4,
Chiara Burgaletto
2,
Giovanni Puglisi
1,
Renato Bernardini
2,* and
Giuseppina Cantarella
2
1
Laboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy
2
Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, 95123 Catania, Italy
3
Dipartimento di Fisica e Astronomia “Ettore Majorana”, Università di Catania, Via Santa Sofia 64, 95123 Catania, Italy
4
CNR-IMM UoS Catania, Istituto per La Microelettronica e Microsistemi, Via Santa Sofia 64, 95123 Catania, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomedicines 2024, 12(11), 2447; https://doi.org/10.3390/biomedicines12112447
Submission received: 24 September 2024 / Accepted: 11 October 2024 / Published: 25 October 2024
(This article belongs to the Special Issue State of the Art: Neurodegenerative Diseases in Italy)
Browse Figure
Versions Notes

Error in Figure

Figure 5 in the original publication [1] was selected by mistake instead of the right one. The subfigures of panel A (a–c′; f′) and panel B (d–f′; g–i′) have now been replaced with the correct version, as the one originally submitted with the manuscript was uploaded by mistake. The corrected Figure 5 now appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Musumeci, T.; Di Benedetto, G.; Carbone, C.; Bonaccorso, A.; Amato, G.; Lo Faro, M.J.; Burgaletto, C.; Puglisi, G.; Bernardini, R.; Cantarella, G. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer’s Disease. Biomedicines 2022, 10, 985. [Google Scholar] [CrossRef] [PubMed]
Biomedicines 12 02447 g005
Figure 5. Comparison of polymeric or lipidic nanoparticles complexed with anti-TRAIL in the hippocampus of 3xTg-AD mice after intranasal administration. Representative immunofluorescence microscopy images showing the localization of the anti-TRAIL monoclonal antibody in the hippocampal sections from WT (A) or 3×Tg-AD (B) mice intranasally administered for 24 h with the anti-TRAIL monoclonal antibody, empty, or anti-TRAIL-loaded NANO-A, NANO-B nanoparticles. The fluorescence signal was detected by using a fluorescent secondary anti-rat IgG. The insets represent the respective areas magnified. (C) The densitometric count of fluorescence was performed with the aid of ImageJ software (available online: https://imagej.nih.gov/ij/ (accessed on 12 January 2022)) and represented as integrated density (% of control). Data are expressed as the mean ± SD. One-way ANOVA followed by Fisher’s LSD test was used for statistical analysis. * p < 0.05. (a–o scale bar = 50 µm; c’, f’, i’, l’, o’ scale bar = 10 µm).
Figure 5. Comparison of polymeric or lipidic nanoparticles complexed with anti-TRAIL in the hippocampus of 3xTg-AD mice after intranasal administration. Representative immunofluorescence microscopy images showing the localization of the anti-TRAIL monoclonal antibody in the hippocampal sections from WT (A) or 3×Tg-AD (B) mice intranasally administered for 24 h with the anti-TRAIL monoclonal antibody, empty, or anti-TRAIL-loaded NANO-A, NANO-B nanoparticles. The fluorescence signal was detected by using a fluorescent secondary anti-rat IgG. The insets represent the respective areas magnified. (C) The densitometric count of fluorescence was performed with the aid of ImageJ software (available online: https://imagej.nih.gov/ij/ (accessed on 12 January 2022)) and represented as integrated density (% of control). Data are expressed as the mean ± SD. One-way ANOVA followed by Fisher’s LSD test was used for statistical analysis. * p < 0.05. (a–o scale bar = 50 µm; c’, f’, i’, l’, o’ scale bar = 10 µm).
Biomedicines 12 02447 g005
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Musumeci, T.; Di Benedetto, G.; Carbone, C.; Bonaccorso, A.; Amato, G.; Lo Faro, M.J.; Burgaletto, C.; Puglisi, G.; Bernardini, R.; Cantarella, G. Correction: Musumeci et al. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer’s Disease. Biomedicines 2022, 10, 985. Biomedicines 2024, 12, 2447. https://doi.org/10.3390/biomedicines12112447

AMA Style

Musumeci T, Di Benedetto G, Carbone C, Bonaccorso A, Amato G, Lo Faro MJ, Burgaletto C, Puglisi G, Bernardini R, Cantarella G. Correction: Musumeci et al. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer’s Disease. Biomedicines 2022, 10, 985. Biomedicines. 2024; 12(11):2447. https://doi.org/10.3390/biomedicines12112447

Chicago/Turabian Style

Musumeci, Teresa, Giulia Di Benedetto, Claudia Carbone, Angela Bonaccorso, Giovanni Amato, Maria Josè Lo Faro, Chiara Burgaletto, Giovanni Puglisi, Renato Bernardini, and Giuseppina Cantarella. 2024. "Correction: Musumeci et al. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer’s Disease. Biomedicines 2022, 10, 985" Biomedicines 12, no. 11: 2447. https://doi.org/10.3390/biomedicines12112447

APA Style

Musumeci, T., Di Benedetto, G., Carbone, C., Bonaccorso, A., Amato, G., Lo Faro, M. J., Burgaletto, C., Puglisi, G., Bernardini, R., & Cantarella, G. (2024). Correction: Musumeci et al. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer’s Disease. Biomedicines 2022, 10, 985. Biomedicines, 12(11), 2447. https://doi.org/10.3390/biomedicines12112447

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop